加载中
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
前收盘价
US$1.47
+US$0.01 · +0.68%
盘中时间采用ET。市场数据可能有所延迟。
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
日内区间
当前US$1.47
52周区间
当前US$1.47
盘中时间采用ET。市场数据可能有所延迟。
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
日内区间
当前US$1.47
52周区间
当前US$1.47
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.09亿 USD | 658.9万 USD | 223.5万 USD | 519.9万 USD | — |
| 销货成本 | 1310.1万 USD | — | — | — | 458.2万 USD |
| 毛利 | 9606.3万 USD | 658.9万 USD | 223.5万 USD | 519.9万 USD | −458.2万 USD |
| 研究与开发 | 9566.7万 USD | 1.07亿 USD | 9271万 USD | 9717.3万 USD | 7564.8万 USD |
| 销售、一般及管理费用 | 2400.3万 USD | 3315.5万 USD | 3470.6万 USD | 3185.7万 USD | 1465.3万 USD |
| 营业费用 | 1.11亿 USD | 1.45亿 USD | 1.49亿 USD | 1.39亿 USD | 9030.1万 USD |
| 利息收入 | 734.6万 USD | 1300.7万 USD | 1267.7万 USD | 299万 USD | 89.8万 USD |
| 利息支出 | — | — | 54万 USD | — | 127.5万 USD |
| 折旧和摊销 | 1310.1万 USD | 1330.4万 USD | 1304.4万 USD | 844万 USD | 374.8万 USD |
| 营业利润 | −1504万 USD | −1.38亿 USD | −1.47亿 USD | −1.34亿 USD | −9488.3万 USD |
| 净利润 | −958万 USD | −1.27亿 USD | −1.37亿 USD | −1.31亿 USD | −9582.4万 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI889.66万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM450.75万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF261.33万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO145.41万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC56.37万0.04%13.17亿 USD0.60%US$183+0.11%
Vanguard Health Care ETFVHT39.35万0.00%220亿 USD0.09%US$319.01+1.64%
Invesco Russell 2000 Dynamic Multifactor ETFOMFS32.53万0.12%2.66亿 USD0.39%US$49.65+0.30%
Avantis U.S. Small Cap Equity ETFAVSC32.02万0.01%30.82亿 USD0.25%US$69.98+0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTInvesco Russell 2000 Dynamic Multifactor ETFOMFSAvantis U.S. Small Cap Equity ETFAVSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
